{
  "docId": "019de073-d2da-762c-9a26-b97a59cfec30",
  "docSlug": "f7af69768ee002be4e2317aa5e807561",
  "documentTitle": "Revelation Biosciences | Investor Presentation Deck | 18 slides",
  "authorId": "revelation-biosciences",
  "authorName": "Revelation Biosciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 18,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a combination of line charts and bar charts to present clinical trial results.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-d2da-762c-9a26-b97a59cfec30/11",
  "deckHref": "/decks/019de073-d2da-762c-9a26-b97a59cfec30",
  "deckJsonHref": "/decks/019de073-d2da-762c-9a26-b97a59cfec30.json",
  "deckAnchorHref": "/decks/019de073-d2da-762c-9a26-b97a59cfec30#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.65,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Phase 2 Virus Challenge Data: % Seroconversion",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b869f7e-f4f8-479a-aafb-8ff3d948de70",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.2,
        "x": 0.38,
        "y": 0.35
      },
      "kind": "chart",
      "text": "IL-7 Percent of Nostrils with >4.5-fold change from baseline",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac2d89c2-7c06-4285-b4b2-09b9886388df",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Phase 1 Biomarker Data: IP10, MCP-1, and IFN-g over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f3a3c77a-2a45-4001-8f2b-d9079e538f1b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.15,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "*Clinical studies were conducted with REVTx-99a which contained PHAD as active ingredient and was being developed as a intranasal prevention for respiratory viral infection",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6b9e09bc-4541-448f-b187-9e8f8b156a26",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.7
      },
      "kind": "list",
      "text": "MCP-1 and IFN-g were also observed and tracked well with IP-10; IL-7 trended in the right direction; PHAD resulted in higher seroconversion.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72e02294-c608-4858-aa61-a8758a844f0d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Phase 1 and Phase 2 Clinical Data* Supports Mechanism of Action",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "833b60db-3be4-4528-9510-03fdb4d5d593",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 15,
      "from": 4,
      "beatId": "2182d072-e6b9-49a0-b466-5a839998139b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 4-15 describe various solutions, including PHAD, REVTx-100, REVTx-200, and REVDx-501.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "f450b0af-f83a-4370-8b16-ab5011fb13d6",
      "evidence": "Slides 4-15 describe PHAD and its applications.",
      "position": 1,
      "objective": "Why is PHAD a well-defined TLR4 agonist with multiple potential applications?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}